These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 36603741)

  • 1. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
    Sellers J; Chang J; Jones J; Hintze TD
    Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.
    Hussain Alsayed HA; Saheb Sharif-Askari F; Saheb Sharif-Askari N; Hussain AAS; Hamid Q; Halwani R
    PLoS One; 2021; 16(10):e0258643. PubMed ID: 34699552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
    JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
    Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
    PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients.
    Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study.
    Mengato D; Mazzitelli M; Francavilla A; Bettio M; Sasset L; Presa N; Pivato L; Lo Menzo S; Trevenzoli M; Venturini F; Gregori D; Cattelan AM
    Clin Exp Med; 2023 Oct; 23(6):2749-2756. PubMed ID: 36961678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital.
    Hidalgo-Tenorio C; García-Vallecillos C; Sequera-Arquelladas S;
    Medicine (Baltimore); 2021 Sep; 100(37):e27228. PubMed ID: 34664862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment.
    Chang MC; Wu PF; Ho YC; Lin WY; Wu CY; Liu SY; Liu CJ; Lin YT
    J Infect Public Health; 2024 Jul; 17(7):102460. PubMed ID: 38820894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.
    Chang HY; Hsu CC; Hu LF; Chou CY; Chang YL; Lu CC; Chang LJ
    Ann Med; 2024 Dec; 56(1):2361843. PubMed ID: 38830017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
    Chavalertsakul K; Sutherasan Y; Petnak T; Thammavaranucupt K; Kirdlarp S; Boonsarngsuk V; Sungkanuparph S
    Int J Gen Med; 2024; 17():2163-2175. PubMed ID: 38770366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use of remdesivir for the treatment of patients admitted to Italian hospitals with COVID-19: the nationwide retrospective FADOI-RECOVER study.
    Pieralli F; Pomero F; Dentali F; Norbiato C; Attardo T; Vicari S; Magnani E; Marzilli MA; Piccolo P; Valerio A; Manfellotto D;
    BMC Infect Dis; 2023 Jul; 23(1):454. PubMed ID: 37422621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State.
    Libra A; Ciancio N; Sambataro G; Sciacca E; Muscato G; Marino A; Vancheri C; Spicuzza L
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
    Joo EJ; Ko JH; Kim SE; Kang SJ; Baek JH; Heo EY; Shi HJ; Eom JS; Choe PG; Bae S; Ra SH; Kim DY; Kim BN; Kang YM; Kim JY; Chung JW; Chang HH; Bae S; Cheon S; Park Y; Choi H; Lee E; Lee BY; Park JW; Sohn Y; Heo JY; Kim SH; Peck KR
    J Korean Med Sci; 2021 Mar; 36(11):e83. PubMed ID: 33754512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.
    Veronese N; Di Gennaro F; Frallonardo L; Ciriminna S; Papagni R; Carruba L; Agnello D; De Iaco G; De Gennaro N; Di Franco G; Naro L; Brindicci G; Rizzo A; Bavaro DF; Garlisi MC; Santoro CR; Signorile F; Balena F; Mansueto P; Milano E; Giannitrapani L; Fiordelisi D; Mariani MF; Procopio A; Lattanzio R; Licata A; Vernuccio L; Amodeo S; Guido G; Segala FV; Barbagallo M; Saracino A
    Sci Rep; 2024 Apr; 14(1):9303. PubMed ID: 38654033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.